Exicure Net Income 2017-2021 | XCUR

Exicure net income from 2017 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Exicure Annual Net Income
(Millions of US $)
2020 $-25
2019 $-26
2018 $-22
2017 $-11
2016 $-17
Exicure Quarterly Net Income
(Millions of US $)
2021-09-30 $-24
2021-06-30 $-14
2021-03-31 $-12
2020-12-31 $-13
2020-09-30 $-9
2020-06-30 $-4
2020-03-31 $1
2019-12-31 $-10
2019-09-30 $-6
2019-06-30 $-5
2019-03-31 $-5
2018-12-31 $-5
2018-09-30 $-5
2018-06-30 $-7
2018-03-31 $-6
2017-12-31 $-3
2017-09-30 $-2
2017-06-30 $-3
2017-03-31 $-3
2016-12-31
2016-09-30 $-4
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.037B $0.017B
Exicure Inc. is a clinical-stage biotechnology company. It is engaged in developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on our proprietary Spherical Nucleic Acid technology. Exicure Inc. is based in IL, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.010B 7.90
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.357B 20.93
Biohaven Pharmaceutical Holding (BHVN) United States $6.783B 0.00
Arcus Biosciences (RCUS) United States $3.105B 0.00
Emergent Biosolutions (EBS) United States $2.254B 8.10
ADC Therapeutics SA (ADCT) Switzerland $1.478B 0.00
Myovant Sciences (MYOV) United Kingdom $1.368B 0.00
Zymeworks (ZYME) Canada $0.861B 0.00
Ambrx Biopharma (AMAM) United States $0.337B 0.00
SQZ Biotechnologies (SQZ) United States $0.319B 0.00
Enzo Biochem (ENZ) United States $0.162B 15.90